{
    "clinical_study": {
        "@rank": "97309", 
        "arm_group": {
            "arm_group_label": "Oxycodone/naloxone", 
            "description": "Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets provided in 56-tablet box. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the efficacy of TARGIN administration as an analgesic to\n      Korean patients treated with opioid analgesics for moderate-to-severe cancer pain under\n      conditions of daily practice."
        }, 
        "brief_title": "PROspective Non-interventional Open laBEl Trial for Assessment in Routine Practice of the Efficacy and the Safety of TARGIN \u00ae in Korean Patients With Cancer Pain (PROBE)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "An open-label, multi-center, nonrandomized, prospective, non-interventional, observational\n      phase IV trial.\n\n      At the first visit, a detailed medical history is taken, including previous analgesics and\n      concomitant treatment. After inclusion, patients enter a 4-week observation period during\n      which they will receive bid of TARGIN 10/5mg and/or 20/10mg. The dose adjustments of TARGIN\n      as well as of analgesic co-medication, rescue-medication and other treatments (e.g.\n      laxatives) can be performed at any time-point during the observation period by the physician\n      in dependence of medical demand. The asymmetric dose is allowed during the observation\n      period by the physician's judgment. (e.g. 10/5 mg in the morning and 20/10 mg in the\n      evening).\n\n      Data are gathered using interview-administered questionnaires at baseline (visit 1) and\n      study end (visit 2).\n\n      During the observation period, unscheduled visits are allowed after the first visit due to\n      inadequate pain control or occurrence of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female cancer patients 20 years of age or older\n\n          2. Cancer related pain that requires treatment with continuous around-the-clock strong\n             opioid analgesic\n\n          3. Moderate to severe pain intensity (NRS pain score >=4)\n\n          4. Opioid na\u00efve patients or patients not treated with strong opioids (Only except\n             occasional  PRN) within 13 months or patients who has been on weak opioids\n\n          5. Ability to communicate effectively with the study personnel regarding pain intensity,\n             constipation assessment, final assessment of overall efficacy and tolerability\n\n          6. Subject who provide signed and dated written voluntary informed consent\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing (lactating) women\n\n          2. Have previously received treatment with Targin\n\n          3. Patient with evidence of significant structural/functional abnormalities of GI tract\n             which is not appropriate for oral medicine administration\n\n          4. Any history of hypersensitivity to Oxycodone and Naloxone or any excipients\n\n          5. Patients with significant respiratory depression\n\n          6. Patients with acute or severe bronchial asthma or hypercarbia\n\n          7. Any patient who has or is suspected of having paralytic ileus\n\n          8. Severe Chronic obstructive pulmonary disease, pulmonary heart disease\n\n          9. Targin product contains lactose. Patients with rare hereditary problems of galactose\n             intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not\n             take\n\n         10. Patients with moderate and severe hepatic impairment\n\n         11. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT;\n             SGPT), or alkaline phosphatase levels (>2.5 times the upper limit of normal, it is\n             allowed >5 times the upper limit of normal in case of transition in liver) or an\n             abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper\n             limit of normal)\n\n         12. Any situation where opioids are contraindicated\n\n         13. With a life expectancy < 1 month\n\n         14. Any situation where opioids are contraindicated\n\n         15. Mainly pain originated other than cancer or cancer related conditions (eg.\n             Musculoskeletal pain, inflammatory pain, diabetic polyneuropathy)\n\n         16. Patients with known or suspected unstable brain metastases or spinal cord compression\n             that may require changes in steroid treatment throughout the duration of the study\n\n         17. Patients with uncontrolled seizures\n\n         18. Requiring interventional treatment for pain such as neurodestructive procedure or\n             regional infusion\n\n         19. With a history of alcohol abuse within 6 months of screening\n\n         20. With a history of illicit drug abuse within 6 months of screening\n\n         21. Patients with increased intracranial pressure\n\n         22. Having used other investigational drugs at the time of enrollment, or within 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary endpoint in the study is the change in numeric rating scales (NRS) such as score\n        for average pain levels over the previous 24 hours.\n\n        In the previous study (U. Schutter, S. Grunert, C. Meyer, T. Schmldt, T. Nolte. Innovative\n        pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large\n        observational study under conditions of daily practice, Current Medical Research &\n        Option), mean change in average pain levels is 2.5 and 95% confidence interval [2.3, 2.7].\n        Based on the result, standard deviation 4.73 is calculated.\n\n        In this study, standard deviation is assumed to be 4.73. Therefore, the sample size is 409\n        considering that significance level is 0.05, confidence interval \u00b10.46. The drop-out rate\n        is considered by 20% then sample size is 512."
            }
        }, 
        "enrollment": {
            "#text": "512", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719757", 
            "org_study_id": "OXN11-KR-404"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Targin, Cancer Pain", 
        "lastchanged_date": "January 29, 2013", 
        "location": {
            "contact": {
                "last_name": "Lee KyungHee, Ph.D", 
                "phone": "82 53 620 3845"
            }, 
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of", 
                    "zip": "705-717"
                }, 
                "name": "Yeungnam University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Yun HwanJung, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Song HongSuk, Ph.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "A 4-week, Open Label, Multi-center, Prospective, Single-arm, Non-interventional Phase IV Study to Evaluate the Efficacy of TARGIN for the Treatment of Korean Patients With Cancer Pain Under Conditions of Daily Practice", 
        "overall_contact": {
            "email": "haeyoung.yang@mundipharma.co.kr", 
            "last_name": "Yang Haeyoung, CRA", 
            "phone": "82-2-527-9223"
        }, 
        "overall_contact_backup": {
            "email": "sunae.shin@mundipharma.co.kr", 
            "last_name": "Shin Ashley, CRM", 
            "phone": "82-2-527-9219"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary objective: Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline (visit 1) to study end (visit 2)", 
            "measure": "Change in numeric rating scales (NRS)", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719757"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in ECOG (Eastern Cooperative Oncology Group Performance at the time of the interview) from baseline (visit 1) to study end (visit 2)", 
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "4weeks"
            }, 
            {
                "description": "Constipation assessment(5-point scale; 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe, for the patient's judgment of the intensity of symptoms)", 
                "measure": "Constipation assessment", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Final assessment of overall efficacy and tolerability by physician and patient", 
                "measure": "Overall satisfaction assessment", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Mundipharma Pte Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Pte Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}